STUDY SEARCH RESULTS

1 study found for your search request:  3475-564

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Ren...
Condition: Renal Cell Carcinoma
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT03142334
Status: Active, not recruiting




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site